GLP-1 receptor agonists and SGLT2 inhibitors reduce the risk of atherosclerotic major adverse cardiovascular events to a comparable degree in patients with type 2 diabetes and established ASCVD. Here, SLC5A2 is linked to type 2 diabetes mellitus.